V 160

Drug Profile

V 160

Alternative Names: Cytomegalovirus vaccine-V160; V-160

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 04 Oct 2017 Adverse events and immunogenicity data from a phase I trial in Cytomegalovirus infections presented at the IDWeek 2017 (IDW-2017)
  • 14 Mar 2017 Merck completes a phase I trial in Cytomegalovirus infections in USA (NCT01986010)
  • 28 Nov 2013 Preclinical trials in Cytomegalovirus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top